Xiaoyi Gong

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Estimating chromatographic enantioselectivity (?) from gradient enantioselective chromatography data
    Xiaoyi Gong
    Separation and Purification Center of Excellence, Merck and Co, Inc, Rahway, New Jersey, USA
    Chirality 23:128-32. 2011
  2. ncbi Simultaneous enantioseparation of a basic active pharmaceutical ingredient compound and its neutral intermediate using reversed phase and normal phase liquid chromatography with a new type of polysaccharide stationary phase
    Lili Zhou
    Merck Research Laboratories, Merck and Co Inc, Rahway, NJ 07065, USA
    J Pharm Biomed Anal 51:153-7. 2010
  3. ncbi Multiparallel microfluidic high-performance liquid chromatography for high-throughput normal-phase chiral analysis
    Peter Sajonz
    Separation and Analysis Technologies, Merck and Co, Inc, Rahway, NJ 07065, USA
    J Chromatogr A 1145:149-54. 2007
  4. ncbi Systematic evaluation of new chiral stationary phases for supercritical fluid chromatography using a standard racemate library
    Zainab Pirzada
    Separation and Purification Center of Excellence, Merck Research Laboratories, Rahway, NJ 07065, USA
    J Chromatogr A 1217:1134-8. 2010
  5. ncbi Factors influencing the interconversion of a new class of dibenzodiazepine sulfonamide atropisomers
    Christopher J Welch
    Merck Research Laboratories, Merck and Co, Inc, Rahway, New Jersey, USA
    Chirality 21:E105-9. 2009
  6. ncbi Microscale HPLC enables a new paradigm for commercialization of complex chiral stationary phases
    Christopher J Welch
    Separation and Purification Center of Excellence, Merck and Co, Inc, Rahway, New Jersey 07065, USA
    Chirality 20:815-9. 2008
  7. ncbi Multiparallel chiral method development screening using an 8-channel microfluidic HPLC system
    Peter Sajonz
    Separation and Analysis Technologies, Process Research, Merck and Co Inc, Rahway, New Jersey 07065, USA
    Chirality 18:803-13. 2006
  8. ncbi Development of LC chiral methods for neutral pharmaceutical related compounds using reversed phase and normal phase liquid chromatography with different types of polysaccharide stationary phases
    Lili Zhou
    Merck Research Laboratories, Merck and Co Inc, Rahway, NJ 07065, USA
    J Pharm Biomed Anal 49:964-9. 2009
  9. ncbi The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization
    Harry R Chobanian
    Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem 20:2845-9. 2012
  10. ncbi Synthesis of 1-tert-butyl-4-chloropiperidine: generation of an N-tert-butyl group by the reaction of a dimethyliminium salt with methylmagnesium chloride
    Joseph S Amato
    Department of Process Research, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065, USA
    J Org Chem 70:1930-3. 2005

Collaborators

Detail Information

Publications10

  1. ncbi Estimating chromatographic enantioselectivity (?) from gradient enantioselective chromatography data
    Xiaoyi Gong
    Separation and Purification Center of Excellence, Merck and Co, Inc, Rahway, New Jersey, USA
    Chirality 23:128-32. 2011
    ..The algorithm was validated for SFC applications and has been shown to accurately predict enantioselectivity for a wide variety of racemic test analytes eluted on different chiral column and mobile phase conditions...
  2. ncbi Simultaneous enantioseparation of a basic active pharmaceutical ingredient compound and its neutral intermediate using reversed phase and normal phase liquid chromatography with a new type of polysaccharide stationary phase
    Lili Zhou
    Merck Research Laboratories, Merck and Co Inc, Rahway, NJ 07065, USA
    J Pharm Biomed Anal 51:153-7. 2010
    ..No matrix interference was observed across the elution windows of compound-A and its intermediate. Additionally, the peak purity of each enantiomer was evaluated by mass spectra, indicating the specificity of the method...
  3. ncbi Multiparallel microfluidic high-performance liquid chromatography for high-throughput normal-phase chiral analysis
    Peter Sajonz
    Separation and Analysis Technologies, Merck and Co, Inc, Rahway, NJ 07065, USA
    J Chromatogr A 1145:149-54. 2007
    ..This represents a considerable improvement over conventional analysis techniques that usually take several days to complete...
  4. ncbi Systematic evaluation of new chiral stationary phases for supercritical fluid chromatography using a standard racemate library
    Zainab Pirzada
    Separation and Purification Center of Excellence, Merck Research Laboratories, Rahway, NJ 07065, USA
    J Chromatogr A 1217:1134-8. 2010
    ..Screening results were archived in a structure-searchable database that allows convenient comparison of performance data to determine which CSPs shows the best performance...
  5. ncbi Factors influencing the interconversion of a new class of dibenzodiazepine sulfonamide atropisomers
    Christopher J Welch
    Merck Research Laboratories, Merck and Co, Inc, Rahway, New Jersey, USA
    Chirality 21:E105-9. 2009
    ....
  6. ncbi Microscale HPLC enables a new paradigm for commercialization of complex chiral stationary phases
    Christopher J Welch
    Separation and Purification Center of Excellence, Merck and Co, Inc, Rahway, New Jersey 07065, USA
    Chirality 20:815-9. 2008
    ....
  7. ncbi Multiparallel chiral method development screening using an 8-channel microfluidic HPLC system
    Peter Sajonz
    Separation and Analysis Technologies, Process Research, Merck and Co Inc, Rahway, New Jersey 07065, USA
    Chirality 18:803-13. 2006
    ..6-mm i.d. columns. In addition, isocratic methods developed on the microbore columns are readily translated to the larger column format...
  8. ncbi Development of LC chiral methods for neutral pharmaceutical related compounds using reversed phase and normal phase liquid chromatography with different types of polysaccharide stationary phases
    Lili Zhou
    Merck Research Laboratories, Merck and Co Inc, Rahway, NJ 07065, USA
    J Pharm Biomed Anal 49:964-9. 2009
    ..The most critical validation aspects, including limit of detection, specificity, and ruggedness, are also briefly presented...
  9. ncbi The design and synthesis of potent, selective benzodiazepine sulfonamide bombesin receptor subtype 3 (BRS-3) agonists with an increased barrier of atropisomerization
    Harry R Chobanian
    Department of Medicinal Chemistry, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Bioorg Med Chem 20:2845-9. 2012
    ..This would thereby make clinical development of this class of compounds more cost effective by inhibiting racemization which can occur over long periods of time at room/elevated temperature...
  10. ncbi Synthesis of 1-tert-butyl-4-chloropiperidine: generation of an N-tert-butyl group by the reaction of a dimethyliminium salt with methylmagnesium chloride
    Joseph S Amato
    Department of Process Research, Merck Research Laboratories, P.O. Box 2000, Rahway, New Jersey 07065, USA
    J Org Chem 70:1930-3. 2005
    ....